Adrián Mosquera Orgueira, MD, PhD,

Adrián Mosquera Orgueira, MD, PhD, is a specialist in Hematology and Hemotherapy and lead researcher of the Computational and Genomic Hematology Group at the Health Research Institute of Santiago de Compostela.

Articles by Adrián Mosquera Orgueira, MD, PhD,

Dr Mosquera Orgueira on the Development of a Machine Learning–Based Prognostic Model for Risk Stratification in Myelofibrosis

ByAdrián Mosquera Orgueira, MD, PhD,

May 29th 2025

Dr Orgueira on Refining the Use of Machine Learning to Predict Survival Outcomes After Transplant in Myelofibrosis

ByAdrián Mosquera Orgueira, MD, PhD,

May 19th 2025

Adrián Mosquera Orgueira, MD, PhD, discusses research to improve machine learning models for predicting post-transplant survival outcomes in myelofibrosis.

Dr Orgueira on the Use of Machine Learning to Predict Survival Outcomes After Allo-HSCT in Myelofibrosis

ByAdrián Mosquera Orgueira, MD, PhD,

April 15th 2025

Adrián Mosquera Orgueira, MD, PhD, discusses whether machine learning could accurately predict OS and NRM outcomes after allo-HSCT in myelofibrosis.

Adrián Mosquera Orgueira, MD, PhD,

Articles by Adrián Mosquera Orgueira, MD, PhD,

Dr Mosquera Orgueira on the Development of a Machine Learning–Based Prognostic Model for Risk Stratification in Myelofibrosis

Dr Orgueira on Refining the Use of Machine Learning to Predict Survival Outcomes After Transplant in Myelofibrosis

Dr Orgueira on the Use of Machine Learning to Predict Survival Outcomes After Allo-HSCT in Myelofibrosis

Latest Updated Articles

Trending on OncLive

FDA Approval of Dostarlimab Brings Potential Organ-Sparing Approach in dMMR Locally Advanced Rectal Cancer

Casdatifan Demonstrates Activity in Advanced Clear Cell RCC

Treatment Tailoring and Weighing Alternative Formulations Support Optimal TKI Deployment in CML

HER2+ Maintenance Therapy Approvals and Innovative Brain Metastasis Care Reshape Breast Cancer Management

Lisaftoclax Plus Acalabrutinib Received Breakthrough Therapy Designation in China for Treatment-Naive CLL/SLL